Navigation Links
American Heart Association Late-Breaking Clinical Trial Report: New Blood Thinner for Angioplasty Patients Not Superior for Primary Endpoint, but Did Reduce Death and Stent Thrombosis
Date:11/15/2009

Study highlights:

- Used during coronary angioplasty plus stenting, in patients who all received clopidogrel after the procedure, a new reversible blood thinner did not have a significantly different effect from placebo on the composite endpoint of all-cause mortality, heart attack and need for new procedures to reopen coronary arteries.

- However, the investigational drug significantly lessened the risk for two pre-specified single secondary endpoints: all-cause mortality and in-stent blood clots.

ORLANDO, Fla., Nov. 15 /PRNewswire-USNewswire/ -- A new reversible blood thinner for angioplasty patients wasn't superior over placebo for its primary combined endpoint of heart attack, all-cause mortality and need for revascularization, but it reduced mortality and in-stent blood clots, researchers reported in a late-breaking clinical trial presentation at the American Heart Association's Scientific Sessions 2009.

CHAMPION PLATFORM, a phase III trial, included 5,362 angioplasty-plus-stent patients randomized to receive either a placebo or the investigational drug cangrelor during procedures to reopen coronary artery blockages. Cangrelor is a potent, fast-acting and reversible anti-clotting drug delivered intravenously.

After their procedures, all patients received 600 milligrams (mg) of the oral, nonreversible anti-clotting drug clopidogrel, which is routinely used in such procedures.

The trial, which enrolled patients beginning in 2006, ended when an interim review committee concluded that cangrelor would fail to show superiority over clopidogrel for its primary endpoint: a composite of all-cause death, heart attack and the need for coronary revascularization procedures.

"There was no statistically significant difference between the two arms of the trial at our 48-hour endpoint," said Deepak L. Bhatt, M.D., M.P.H., chief of cardiology at the VA Boston Healthcare System.
'/>"/>

SOURCE American Heart Association
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Zargis to Release Trial Version of Cardioscan while Exhibiting with 3M(TM) Littmann(R) at American Heart Association Conference
2. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
3. VisEn Launches New Cat B 750 Fast(TM) Fluorescence Molecular Imaging Agent at American Heart Association Meeting
4. Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
5. American Oriental Bioengineering to Report Third Quarter 2009 Financial Results on November 16, 2009
6. ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)
7. California American Water Celebrates No Drugs Down the Drain Week in San Diego
8. VIA Pharmaceuticals Featured at American Heart Association Scientific Sessions 2009
9. American Regent Expands Voluntary Recall to Include All Lots of Ketorolac Tromethamine Injection, USP 15 mg/mL; 1mL Single Dose Vials
10. Educational Video Series Released for American Diabetes Month
11. CyberKnife to be Focus of Numerous Presentations at the American Society for Radiation Oncology (ASTRO) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013 Oramed Pharmaceuticals Inc. (NASDAQCM: ... delivery systems, announced today that the United States Food ... New Drug application(IND) for ORMD-0801, its oral insulin capsule. ... FDA clearance to proceed," stated Nadav Kidron ... a major milestone for Oramed and we look forward ...
(Date:5/17/2013)...  Boston Scientific Corporation (NYSE: BSX ) ... Program May 21-24 in Paris . ... rich and diversified set of data this year at ... global chief medical officer, Boston Scientific.  "The primary endpoint ... NG PROMUS trial, which evaluated our Promus PREMIER ™ ...
(Date:5/16/2013)... and MECHELEN, Belgium , May 17, ... (NYSE: ABBV ) announced today an extension ... disease.  Galapagos will fund and complete a Phase 2 ... rapid progression into Phase 3.  Upon successful completion of ... Galapagos $50 million.  The terms of the collaboration extension ...
Breaking Medicine Technology:Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 2Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 4Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 5Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 7Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 8AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 2AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 4AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 5AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 6
... and TARRYTOWN, N.Y., March 19, 2012   Siemens Healthcare Diagnostics ... for Clinical Pathology (ASCP) have awarded ... and graduate medical laboratory students for the 2011-2012 academic year. ... was established in 2003 to address the nation,s ...
... 2012 Avaxia Biologics, Inc., a privately-held biotech company ... therapeutics for the treatment of gastrointestinal diseases, is proud ... of funding from the National Institutes of Health for ... been awarded a Phase II Small Business Innovation Research ...
Cached Medicine Technology:Siemens and ASCP Award Over 100 Scholarships to Medical Laboratory Students in 2012 2Siemens and ASCP Award Over 100 Scholarships to Medical Laboratory Students in 2012 3Avaxia Biologics Awarded $1.5 Million Phase II SBIR Grant from NIH to Develop Oral Antibody Therapeutic for Inflammatory Bowel Disease 2
(Date:5/18/2013)... (May 19, 2013) The American Gastroenterological Association ... 2013 research scholars. This year,s honorees are outstanding ... hepatology or related areas, and with this award, ... "These young researchers are the future of our ... who are paving the way for promising research ...
(Date:5/18/2013)... News) -- Children who swallow high-powered magnets often need ... according to a new study. The researchers, from ... found that more than 79 percent of children who ... an endoscopic procedure, in which a tube containing a ... percent of these cases can be treated through observation ...
(Date:5/18/2013)... is associated with a reduced risk of primary ... Clinic research shows. The findings were being presented ... Orlando, Fla. , PSC is an inflammatory ... inflammation and subsequent fibrosis that can lead to ... cancer. , "While rare, PSC has extremely detrimental ...
(Date:5/18/2013)... May 18, 2013 Transvaginal mesh ... continue to move forward in a consolidated litigation underway ... LLP reports. According to a notice on the Court’s ... pelvic mesh litigation will be held on Wednesday, May ... been filed in the proceeding on behalf of women ...
(Date:5/18/2013)... 18, 2013 TheBeautyPlace.com answers important questions ... loss is not a result of stress, nutrient deficiency ... Fitness Magazine, 70% of men suffer from male patterned ... is renowned for hair transplant surgery, but additionally carries ... baldness known as Bosley Professional Strength. Their product line ...
Breaking Medicine News(10 mins):Health News:AGA Research Foundation Research Scholar Awards advance the work of promising gastroenterologists 2Health News:Swallowing Magnets Can Be Fatal for Children 2Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 2Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 3Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 2Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 3
... pregnancy and childbirth are less likely to involve in ... with their newborns, interacting with // them etc. The ... the impact of mother’s depressive symptoms on her parenting ... behavior of more than 4,874 mothers from nearly 15 ...
... foods are under-diagnosed and under-treated, both in the community ... the American // Academy of Allergy, Asthma, and ... General Hospital in Boston and the Albany (N.Y.) Medical ... of Manitoba in Winnipeg, who is president of the ...
... Legionnaires disease thrives in poorly-maintained air-conditioning towers.,It is an air ... 10 days after initial exposure. // ,Symptoms include ... outbreak occurred in the north of Melbourne. So far ten ... 51-year-old man was tested positive to the airborne disease and ...
... A study conducted by Anna Johnson, a doctoral candidate ... that military veterans suffer from increased risk of heart ... found that combat veterans suffer 10-year risk of heart ... non-veterans. The results were presented at the American Heart ...
... York's Columbia University suggests that almost three-quarters of the ... two genes. AMD happens to be one of the ... "I am not aware of any other complex disorder ... said lead researcher Dr Rando Allikmets. "These findings are ...
... the dreaded bird flu had made an entry into neighboring Poland. ... died of bird flu. Since then the country has instituted a ... and Protection of Consumer Minister Horst Seehofer has said that cats ... homes, while it is compulsory to keep dogs on leashes. Entering ...
Cached Medicine News:Health News:Depressive Mothers Do Not Play Enough With Their Infants 2Health News:Number of Allergic Anaphylaxis Episodes Are Far More Than Those Recorded 2
... Infinity Triglycerides powder reagent once reconstituted ... of single liquid stability to help ... and provide quick result turnaround time. ... Triglycerides powder reagent provides a long ...
... liquid stable reagent offers the laboratory ... stability to help maximize laboratory productivity, ... result turnaround time. The patented technology ... a long shelf life that will ...
... Creatinine single liquid stable reagent offers ... single liquid stability to help maximize ... provide quick result turnaround time. The ... reagent provides a long shelf life ...
... The Infinity Amylase powder reagent ... the convenience of single liquid stability ... operator error and provide quick result ... the Infinity Amylase powder reagent provides ...
Medicine Products: